Abzu® announced that the United States Patent and Trademark Office (USPTO) has issued Abzu Aps a patent number US 11,537,686 titled “Method of Deriving a Correlation” that protects the technology behind the pioneering QLattice algorithm.
Abzu’s proprietary discovery engine, the QLattice, is an artificial intelligence that enables scientists and researchers to answer “why” questions.
“People who invent and build methods for AI should stop chasing ever more complicated and predictive methods and see if we could instead put the vast potential of AI at the service of science. At Abzu, we have built an AI — the QLattice — that is actually intelligent in the scientific sense of the word,” says Casper Wilstrup, CEO and one of seven co-founders of Abzu.
“Why” questions, especially when humans increasingly rely on automated computational systems to handle vast amounts of complex data, have historically gone unanswered. This is because traditional AI produces “black-box” models: Models that are good at predicting what will happen, but are terrible at explaining “why” something will happen.
This inability to understand a system’s internal logic has stymied scientists and researchers in life science industries. Such scientists, as well as their theories, rely on understanding the “why”: E.g., “Why does this disease occur?” or “Why does this drug treat this disease?”
“This is a significant achievement for Abzu,” says Victor Galindo, Software Engineer and one of seven co-founders of Abzu. “The patent granted by USPTO proves that we are on the right track to getting a novel technology into the world.”
Victor, Casper, and all the Abzoids believe scientists and AI researchers can work together to put theory back into the heart of science – where it belongs.
The U.S. patent will expire in 2040.
Founded in 2018, Abzu® builds trustworthy AI to tackle complex challenges for the world’s leading companies. Abzu established itself as a global leader in explainable, rational, and safe AI in the pharmaceutical industry, contributing to new discoveries in disease understanding and RNA therapeutics. Today, Abzu’s technology accelerates new insights and understanding in pharma R&D and transforms critical and complex business processes for enterprise operations.
Abzu has offices in Copenhagen and Barcelona, and has raised €13.3M in total funding to date. Abzu has been mentioned in Gartner® research, from Market Guides for AI Trust, Risk, and Security Management to CoolVendor™, and is the winner of several awards, including the 2023 “Best HealthTech” Nordics Award at the Nordic Startup Awards. For more information, visit www.abzu.ai.